Download to the doc

Carvi Beta
Carvi Beta
Systematic (IUPAC) name
(±)-[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine
Chemical data
Formula
C24H26N2O4
Pharmacokinetic data
Bioavailability
25–35%
Protein binding
98%
Metabolism
Half-life
Excretion
Liver (CYP2D6, CYP2C9)
7–10 hours
Urine (16%), Feces (60%)
Therapeutic considerations
Legal status
Routes
℞ Prescription only
Oral
Carvi Beta is a non-selective beta blocker/alpha-1 blocker indicated in the treatment of
mild to moderate congestive heart failure (CHF).

Pharmacology
Carvi Beta is both a beta blocker (β1, β2) and alpha blocker (α1):

Norepinephrine stimulates the nerves that control the muscles of the heart by
binding to the β1- and β2-adrenergic receptors. Carvi Beta blocks the binding to
those receptors, which both slows the heart rhythm and reduces the force of the
heart's pumping. This lowers blood pressure and reduces heart failure.

Norepinephrine also binds to the α1-adrenergic receptors on blood vessels,
causing them to constrict and raise blood pressure. Carvi Beta blocks this
binding to the α1-adrenergic receptors too which also lowers blood pressure.
Relative to other beta blockers, Carvi Beta has minimal inverse agonist activity. This
suggests that Carvi Beta has a reduced negative chronotropic and inotropic effect
compared to other beta blockers, which may decrease its potential to worsen symptoms
of heart failure. However, to date this theoretical benefit has not been established in
clinical trials, and the current version of the ACC/AHA guidelines on congestive heart
failure management does not give preference to Carvi Beta over other beta-blockers.
Side effects
The most common side effects include dizziness, fatigue, hypotension, diarrhea,
asthenia, bradycardia, and weight gain.
A case report of a patient with panic disorder associated sleep disturbances and
nightmares with the improper usage of Carvi Beta.[6]
Clinical use
Carvi Beta is indicated in the management of congestive heart failure (CHF), as an
adjunct to conventional treatments (ACE inhibitors and diuretics). The use of Carvi Beta
has been shown to provide additional morbidity and mortality benefits in CHFCarvi Beta
is available at the following doses 3.125 mg (smallest), followed by 6.25 mg, 12.5 mg,
and 25 mg white tablets.